{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:06:34Z","timestamp":1790179594398,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:00:00Z","timestamp":1762646400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016396","name":"Association Fran\u00e7aise d'Urologie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The French Journal of Urology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.fjurol.2025.102998","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:36:25Z","timestamp":1760006185000},"page":"102998","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chemotherapy use in triplet approach for metastatic hormone-sensitive prostate cancer: French practice survey and expert opinion"],"prefix":"10.1016","volume":"35","author":[{"given":"Delphine","family":"Borchiellini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwenaelle","family":"Gravis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Hannoun-Levi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Berdah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Chapet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Chebbah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solenn","family":"Le Clanche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Descotes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Ruffion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Maillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Pignot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.fjurol.2025.102998_bib0175","series-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on prostate cancer 2022","author":"Mottet","year":"2022"},{"key":"10.1016\/j.fjurol.2025.102998_bib0180","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.fjurol.2025.102998_bib0185","unstructured":"Institut national du cancer. Le cancer de la prostate n.d. https:\/\/www.e-cancer.fr\/Professionnels-de-sante\/Les-chiffres-du-cancer-en-France\/Epidemiologie-des-cancers\/Les-cancers-les-plus-frequents\/Cancer-de-la-prostate (accessed January 3, 2024)"},{"key":"10.1016\/j.fjurol.2025.102998_bib0190","unstructured":"International Agency for Research on Cancer WHO. Globocan 2020 n.d."},{"key":"10.1016\/j.fjurol.2025.102998_bib0195","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/JU.0000000000001375","article-title":"Advanced Prostate Cancer: AUA\/ASTRO\/SUO Guideline PART I","volume":"205","author":"Lowrance","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2025.102998_bib0200","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2217\/fon-2023-0814","article-title":"Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia","volume":"20","author":"Goebell","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.fjurol.2025.102998_bib0205","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.fjurol.2025.102998_bib0210","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fjurol.2025.102998_bib0215","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.2217\/fon-2022-0433","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial","volume":"18","author":"Smith","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.fjurol.2025.102998_bib0220","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1200\/JCO-24-01798","article-title":"Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial","volume":"42","author":"Saad","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.fjurol.2025.102998_bib0225","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fjurol.2025.102998_bib0230","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fjurol.2025.102998_bib0235","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fjurol.2025.102998_bib0240","doi-asserted-by":"crossref","first-page":"102717","DOI":"10.1016\/j.fjurol.2024.102717","article-title":"French AFU Cancer Committee Guidelines\u00a0\u2013\u00a0update 2024\u20132026: prostate cancer\u00a0\u2013\u00a0diagnosis and management of localised disease","volume":"34","author":"Ploussard","year":"2024","journal-title":"Fr J Urol"},{"key":"10.1016\/j.fjurol.2025.102998_bib0245","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2025.102998_bib0250","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.annonc.2023.02.015","article-title":"Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents","volume":"34","author":"Fizazi","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.fjurol.2025.102998_bib0255","series-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): prostate cancer. Version 1.2025. Published March 13, 2024","year":"2025"},{"key":"10.1016\/j.fjurol.2025.102998_bib0260","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u00d72 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.fjurol.2025.102998_bib0265","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fjurol.2025.102998_bib0270","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.fjurol.2025.102998_bib0275","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12894-022-00979-9","article-title":"Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan","volume":"22","author":"Leith","year":"2022","journal-title":"BMC Urol"},{"key":"10.1016\/j.fjurol.2025.102998_bib0280","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fjurol.2025.102998_bib0285","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fjurol.2025.102998_bib0290","doi-asserted-by":"crossref","first-page":"e0179694","DOI":"10.1371\/journal.pone.0179694","article-title":"The G8 screening tool enhances prognostic value to ECOG performance status in elderly cancer patients: a retrospective, single institutional study","volume":"12","author":"Takahashi","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.fjurol.2025.102998_bib0295","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jgo.2020.10.017","article-title":"Validation of the G8 screening tool in older patients with cancer considered for surgical treatment","volume":"12","author":"Bruijnen","year":"2021","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.fjurol.2025.102998_bib0300","unstructured":"Urofrance\u00a0|\u00a0French AFU Cancer Committee Guidelines\u00a0\u2013\u00a0update 2022\u20132024: prostate cancer\u00a0\u2013\u00a0management of metastatic disease and castration resistance\u00a0\u2013\u00a0Urofrance n.d. https:\/\/www.urofrance.org\/recommandation\/french-afu-cancer-committee-guidelines-update-2022-2024-prostate-cancer-management-of-metastatic-disease-and-castration-resistance\/ (accessed March 21, 2025)."},{"key":"10.1016\/j.fjurol.2025.102998_bib0305","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1200\/JCO.20.03256","article-title":"Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO Guideline Update","volume":"39","author":"Virgo","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.fjurol.2025.102998_bib0310","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.fjurol.2025.102998_bib0315","unstructured":"ESMO. Triplet therapy with ADT, docetaxel and abiraterone plus prednisone improves survival in de novo metastatic castration-sensitive prostate cancer n.d. https:\/\/www.esmo.org\/oncology-news\/triplet-therapy-with-adt-docetaxel-and-abiraterone-plus-prednisone-improves-survival-in-de-novo-metastatic-castration-sensitive-prostate-cancer (accessed February 6, 2025)."},{"key":"10.1016\/j.fjurol.2025.102998_bib0320","unstructured":"ESMO. Darolutamide in combination with ADT and docetaxel increases overall survival in patients with metastatic hormone-sensitive prostate Cancer n.d. https:\/\/www.esmo.org\/oncology-news\/darolutamide-in-combination-with-adt-and-docetaxel-increases-overall-survival-in-patients-with-metastatic-hormone-sensitive-prostate-cancer (accessed February 6, 2025)."},{"key":"10.1016\/j.fjurol.2025.102998_bib0325","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/s41391-021-00389-2","article-title":"Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer","volume":"24","author":"Lage","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.fjurol.2025.102998_bib0330","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2025.43.5_suppl.20","article-title":"Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD)","volume":"43","author":"Fisher","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.fjurol.2025.102998_bib0335","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1200\/JCO.2025.43.5_suppl.143","article-title":"Age-related efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) and docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subgroup analysis of ARASENS","volume":"43","author":"Carles","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.fjurol.2025.102998_bib0340","series-title":"Conseil national de l\u2019Ordre des m\u00e9decins","year":"2024"}],"container-title":["The French Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393025001457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393025001457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:46:08Z","timestamp":1790178368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950393025001457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2950393025001457"],"URL":"https:\/\/doi.org\/10.1016\/j.fjurol.2025.102998","relation":{},"ISSN":["2950-3930"],"issn-type":[{"value":"2950-3930","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemotherapy use in triplet approach for metastatic hormone-sensitive prostate cancer: French practice survey and expert opinion","name":"articletitle","label":"Article Title"},{"value":"The French Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fjurol.2025.102998","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"102998"}}